Ziv-aflibercept

Search with Google Search with Bing

Information
Drug Name
Ziv-aflibercept
Description
Entry(CIViC)
CIViC
[No Data.]
Annotation
NCT ID Status Phase Summary Start date Completion date
NCT02298959 Active, not recruiting Phase 1 Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer April 8, 2015 December 31, 2024
NCT00045266 Completed Phase 1 VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma April 2002
NCT00082823 Completed Phase 1 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma January 2004
NCT00083213 Completed Phase 1 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma January 2004
NCT00369590 Completed Phase 2 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide August 2006 October 2012
NCT00369655 Completed Phase 2 VEGF Trap in Treating Patients With Metastatic Breast Cancer January 2007 January 2011
NCT00390234 Completed Phase 2 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma September 2006 August 2013
NCT00407485 Completed Phase 2 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium November 2006 April 2014
NCT00436501 Completed Phase 1/Phase 2 VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer January 2007 November 2012
NCT00450255 Completed Phase 2 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery June 2007 January 2011
NCT00462826 Completed Phase 2 VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer November 2007 January 2013
NCT00622414 Completed Phase 1 Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors April 2008
NCT00650923 Completed Phase 1 Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma July 2008 December 2013
NCT00729157 Completed Phase 2 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy August 2008 November 2012
NCT00828139 Completed Phase 2 S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer May 2009 September 2012
NCT01258855 Completed Phase 2 Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery January 18, 2011 March 29, 2018
NCT01747551 Completed Phase 2 FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer January 2013 July 26, 2017
NCT01782443 Completed Phase 2 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors February 13, 2013 December 26, 2021
NCT00036946 Completed Phase 1 VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma November 2001
NCT02101918 Completed Phase 2 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery June 18, 2014 January 31, 2018
NCT02159989 Completed Phase 1 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery June 18, 2014 January 29, 2024
NCT03712904 Completed Phase 2 Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma August 9, 2019 December 23, 2022
NCT06121180 Recruiting Phase 2 Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma February 9, 2024 October 31, 2030
NCT02192541 Terminated Phase 1 Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas December 2, 2014 February 25, 2016
NCT00509249 Terminated Phase 2 Aflibercept in Treating Patients With Myelodysplastic Syndromes September 2007 December 2010
NCT02486484 Unknown status Phase 2 Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection March 2015 December 2019
NCT02235324 Withdrawn Phase 2 Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer March 2015 March 2018
NCT01889680 Withdrawn Phase 2 Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer November 2014 May 2018
NCT01941173 Withdrawn N/A Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy January 2014